For all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care, explained David A. Eagle, MD, New York Cancer & Blood Specialists.
David A. Eagle, MD, chair of legislative affairs and patient advocacy at New York Cancer & Blood Specialists, explains how even progress has its drawbacks, as for all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care.
Transcript
In the past 2-plus decades, what have been some of the biggest advancements in hematology/oncology?
The biggest advantages have clearly been on the scientific level: immunotherapy, targeted therapy. It begins with oncogenes, where we finally figured out, really, what makes a cancer a cancer. That’s clearly been the biggest progress in oncology. The problem is, as we talked about earlier, that that’s creating a natural tension between what we can do for patients and how we actually pay for that care.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More